This week, AMO Pharma Limited announced the commencement of patient recruitment for an interventional study of AMO-01, an investigational Ras-ERK pathway inhibitor for the treatment of Phelan-McDermid syndrome (PMS). “Treatment of Phelan-McDermid syndrome represents a significant area of unmet need in healthcare, and AMO Pharma is grateful to the research team at Mt. Sinai as well as the Phelan McDermid Syndrome Foundation for their commitment to this landmark research effort,” said Michael Snape, PhD, CEO of AMO Pharma. “Research thus far indicates that AMO-01 could have important applications in the treatment of patients living with Phelan-McDermid syndrome in the years ahead.”
A rare but life-threatening immune reaction in response to lamotrigine (Lamictal) requires prompt diagnosis and treatment, according to a recent alert from the U.S. Food and Drug Administration (FDA). On April 25, the FDA issued what it calls a “drug safety communication” about the risk of a condition so rare that few neurologists have heard of it: hemophagocytic lymphohistiocytosis (HLH), a systematic immune reaction that can result in organ failure and death if not quickly treated. Just eight such cases associated with lamotrigine, including one death, are known by the FDA to have occurred since the drug was first approved in 1994 as a treatment for epilepsy. Since then, it has also been approved for bipolar disorder, and is now increasingly prescribed off-label...
Exposure to sodium valproate or a combination of antiepileptic drugs (AEDs) in utero is associated with worse attainment on national educational tests for 7-year-olds, according to a study published online March 26 in the Journal of Neurology, Neurosurgery & Psychiatry. Arron S. Lacey, from Swansea University Medical School in the United Kingdom, and colleagues identified children born to mothers with epilepsy and linked these children to their national attainment Key Stage 1 (KS1) tests in mathematics, language, and science at age 7. The children were compared with matched children born to mothers without epilepsy.
Brain training devised by a Brighton clinical researcher can cut the number and frequency of epileptic seizures in patients who have not responded to drug treatment. Details of the groundbreaking research have been published in The Lancet and Cell Press journal Ebiomedicine. One in 100 people suffer with epilepsy – 50 million people worldwide – with about 30 per cent of them apparently unable to benefit from drugs to manage the condition. About half of those taking part in clinical trials reported that the technique reduced seizures by 50 per cent or more. It was invented by Yoko Nagai, Wellcome Trust Research Fellow at the Brighton and Sussex Medical School, run jointly by Brighton University and Sussex University. The technique is seen as an alternative...
Rice University researchers have invented a device that uses fast-moving fluids to insert flexible, conductive carbon nanotube fibers into the brain, where they can help record the actions of neurons. The Rice team’s microfluidics-based technique promises to improve therapies that rely on electrodes to sense neuronal signals and trigger actions in patients with epilepsy and other conditions.
A study has revealed that ultrasound can be key in the treatment of Parkinson’s Disease and other neurological diseases (including epilepsy) in the future. An experiment that tested a macaque monkey and sheep has revealed that directing bursts of inaudible acoustic energy at a specific visual area of the brain can control the animals’ responses. The results, which were presented at the annual Society for Neuroscience meeting held recently, revealed that focused ultrasound used in the said animals could safely and effectively alter brain activity rather than destroy tissue.
Several new Australian-developed medicines showing promise treating childhood epilepsy, stroke and autoimmune diseases have emerged from an unusual source: the fangs of venomous creatures. Big pharmaceutical companies are excited by results showing these new venom-drugs are often superior to man-made drugs, and they are starting to pour money into research.
Treatment with cannabidiol reduces some major symptoms in mice with a genetic condition recapitulating Dravet syndrome, a devastating childhood brain disorder. Cannabidiol is a non-intoxicating substance among the several active compounds derived from Cannabis plants. This molecule can also be produced synthetically. The results of its use to treat Dravet syndrome are reported in the latest edition of the Proceedings of the National Academy of Sciences, PNAS.
People with certain types of epilepsy may have the option to use a therapy that doesn’t include drugs. The RNS System from NeuroPace, a company out of Mountain View, California, monitors the brain for signs of an oncoming seizure and stimulates it to disrupt the process. It has been approved in the U.S. for about four years now, and we wanted to find more about how it works and how it’s being used. We had a chance to speak with Dr. Martha Morrell, Chief Medical Officer of NeuroPace, who was kind enough to answer our questions. Medgadget: The NeuroPace RNS system has shown to be effective at reducing seizures in many patients with epilepsy. Can you give us a brief overview of how the system functions?
Scientists are increasingly appreciating estrogen’s role in brain health. Now for the first time, production of estrogen in the brain has been directly linked to the presence of docosahexaenoic acid (DHA). DHA is found in abundance in fish oils and is also synthesized from alpha-linolenic acid, an omega-3 fatty acid found in some vegetable-based oils.
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial. The trial dubbed as STAR 1 was held in 188 adult epilepsy patients with focal seizures across 14 sites in Australia and New Zealand. When compared to placebo, ZYN002 during the treatment period could not show a statistically significant decrease in focal seizures in comparison to the baseline period for either the high or low dose cohorts. STAR expands to Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy. The patients in the phase 2 trial were randomized to be treated during a 12-week period for every 12 hours with either 195mg of ZYN002 4.2% CBD gel, 97.5mg of ZYN002 4.2% CBD gel or placebo gel. The primary...